clinical trials

Scientists in the UK have successfully used gene therapy to restore some vision to legally blind children with an inherited retinal condition. All 11 children in the clinical trial saw improvements within weeks of a single surgical treatment.

One of cancer’s deadliest tricks is its ability to spread to other organs. An existing cardiac drug has now been found to reduce the risk of metastasis by dissolving circulating clusters of breast cancer cells in patients.

A phase 3 clinical trial has shown that adding an immunotherapy drug to chemotherapy almost doubled the cure rate for patients with the most common kind of breast cancer. The findings suggest that a new treatment paradigm should be adopted.

Prostate cancer is usually treated with surgery and radiation therapy, but these can have drastic side effects. A new clinical trial is exploring the safety and efficacy of killing the cancer cells with a blast of steam.

Hugely promising cancer immunotherapy drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration granted it Breakthrough Therapy Designation status that, if successful, will expedite its path to market.

For the first time, there's scientific evidence that a smaller, lesser known component of cannabis – cannabinol – delivers better quality and longer sleep. It proved to be comparable to existing sleep aids, without the undesirable side effects.

Game-changing GLP-1 agonist drugs are a step closer to being available in oral pill form, with AstraZeneca revealing "encouraging data" from the Phase I safety and tolerability trial of its once-daily obesity and diabetes drug AZD5004.

While growing evidence suggests that there’s a link between blood iron levels and the development of Alzheimer’s disease, new research investigating the effects of an available iron-reducing drug has raised concerns about its use as a treatment for the condition.

A new review has highlighted how skin tone can affect the safety and effectiveness of some medications and why the current way we run clinical drug trials needs to change to include more historically underrepresented populations.